Overview

Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.
Phase:
Phase 3
Details
Lead Sponsor:
Upsher-Smith Laboratories
Treatments:
Topiramate